{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:52:01Z","timestamp":1791579121066,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014850","name":"Bayer Consumer Care AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.euf.2026.02.005","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:48:44Z","timestamp":1772128124000},"page":"743-751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy"],"prefix":"10.1016","volume":"12","author":[{"given":"Andrew L.","family":"Laccetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr","family":"Nowfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Einstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Adorjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjari","family":"Dissanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verholen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.02.005_b0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2026.02.005_b0010","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2026.02.005_b0015","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2026.02.005_b0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000481438","article-title":"Management of biochemical recurrence after primary curative treatment for prostate cancer: a review","volume":"100","author":"Artibani","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2026.02.005_b0025","first-page":"1194","article-title":"Assessment of biochemical recurrence of prostate cancer (Review)","volume":"55","author":"Lin","year":"2019","journal-title":"Int J Oncol"},{"key":"10.1016\/j.euf.2026.02.005_b0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41391-023-00711-0","article-title":"Application of next-generation imaging in biochemically recurrent prostate cancer","volume":"27","author":"Moul","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2026.02.005_b0035","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.02.005_b0040","article-title":"Improved survival with enzalutamide in biochemically recurrent prostate cancer","author":"Shore","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.02.005_b0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","article-title":"A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)","volume":"158","author":"Maluf","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2026.02.005_b0050","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","article-title":"Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study","volume":"15","author":"Tombal","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.02.005_b0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.euros.2021.09.015","article-title":"Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy","volume":"34","author":"Autio","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2026.02.005_b0060","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.euf.2026.02.005_b0065","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug-drug interaction potential of darolutamide: in vitro and clinical studies","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.euf.2026.02.005_b0070","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.euf.2026.02.005_b0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11523-023-00959-5","article-title":"Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: a randomized crossover trial","volume":"18","author":"Williams","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.euf.2026.02.005_b0080","unstructured":"Bayer HealthCare Pharmaceuticals Inc. NUBEQA (darolutamide) Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212099Orig1s000lbl.pdf (accessed November 2025)."},{"key":"10.1016\/j.euf.2026.02.005_b0085","unstructured":"Bayer HealthCare Pharmaceuticals Inc. NUBEQA (darolutamide) Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nubeqa-epar-product-information_en.pdf (accessed November 2025)."},{"key":"10.1016\/j.euf.2026.02.005_b0090","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.02.005_b0095","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.02.005_b0100","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.02.005_b0105","unstructured":"Morgans AK, Haresh KP, Minduagas J, et al. Pain and health-related quality of life outcomes with darolutamide: secondary\u202fand exploratory analyses of the phase 3 randomised, placebo-controlled ARANOTE trial Lancet Oncol 2026; (In Press)."},{"key":"10.1016\/j.euf.2026.02.005_b0110","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.euo.2024.01.009","article-title":"A phase 2 randomized open-label study of oral darolutamide monotherapy versus androgen deprivation therapy in men with hormone-sensitive prostate cancer (EORTC-GUCG 1532)","volume":"7","author":"Tombal","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2026.02.005_b0115","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40262-023-01268-w","article-title":"Clinical pharmacokinetics and pharmacodynamics of the next generation androgen receptor inhibitor-darolutamide","volume":"62","author":"Podgor\u0161ek","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.euf.2026.02.005_b0120","first-page":"205","article-title":"Prophylactic Breast Irradiation for Prevention of Bicalutamide-induced Painful Gynecomastia in Patients with Low- and Intermediate-risk Prostate Cancer","volume":"25","author":"Chernomordikov","year":"2023","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.euf.2026.02.005_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136094","article-title":"Gynecomastia in patients with prostate cancer: a systematic review","volume":"10","author":"Fagerlund","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2026.02.005_b0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00066-020-01598-9","article-title":"Treatment strategies to prevent and reduce gynecomastia and\/or breast pain caused by antiandrogen therapy for prostate cancer : statement from the DEGRO working group prostate cancer","volume":"196","author":"Ghadjar","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.euf.2026.02.005_b0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euros.2025.01.001","article-title":"Incidence, management, and prevention of gynecomastia and breast pain in patients with prostate cancer undergoing antiandrogen therapy: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Tsuboi","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2026.02.005_b0140","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2022.1641","article-title":"Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial","volume":"8","author":"Shore","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2026.02.005_b0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.150","article-title":"Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results","author":"Laccetti","year":"2025","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.euf.2026.02.005_b0150","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.02.005_b0155","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.02.005_b0160","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40262-021-01078-y","article-title":"Clinical pharmacokinetics of the androgen receptor inhibitor darolutamide in healthy subjects and patients with hepatic or renal impairment","volume":"61","author":"Zurth","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.euf.2026.02.005_b0165","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40262-023-01268-w","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide","volume":"62","author":"Podgorsek","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.euf.2026.02.005_b0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40336-023-00582-4","article-title":"PSMA PET\/CT and PET\/MRI in primary staging of prostate cancer and its effect on patient management","volume":"12","author":"Claes","year":"2024","journal-title":"Clin Trans Imag"},{"key":"10.1016\/j.euf.2026.02.005_b0175","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2967\/jnumed.124.268275","article-title":"Prospective head-to-head comparison of 18F-PSMA PET\/CT and 18F-NaF PET\/CT for assessing bone metastases in 160 patients with newly diagnosed high-risk prostate cancer","volume":"66","author":"Madsen","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.02.005_b0180","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.52971","article-title":"PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging","volume":"8","author":"Holzgreve","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:36:14Z","timestamp":1791578174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2405456926000349"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.02.005","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}